NCT06345014 - The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

March 30, 2026

Conditions

Chronic Prostatitis With Chronic Pelvic Pain SyndromeChronic ProstatitisChronic Pelvic Pain Syndrome

Interventions

DRUG

OM-89 [Uro-Vaxom® Capsule]

Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day

DRUG

OM-89 Placebo [Uro-Vaxom® Capsule Placebo]

Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)

Trial Locations (1)

RECRUITING

AJU Pharm Co., Ltd., Seoul